Suppr超能文献

肠膨出不是经肛吻合术治疗出口梗阻的禁忌证:170 例患者分析。

Enterocele is not a contraindication to stapled transanal surgery for outlet obstruction: an analysis of 170 patients.

机构信息

Department of General, Visceral, Vascular and Pediatric Surgery, University Hospital of Wuerzburg, Wuerzburg, Germany.

出版信息

Colorectal Dis. 2011 Jun;13(6):e131-6. doi: 10.1111/j.1463-1318.2011.02554.x.

Abstract

AIM

Enterocele is common among patients suffering from obstructive defecation syndrome (ODS), but it is often considered a contraindication for stapled transanal surgery. The functional results and complication rates were compared in patients with or without enterocele who were treated with stapled transanal rectal resection (STARR) for ODS.

METHOD

Patients presenting with ODS were evaluated using standardized clinical and radiological investigations. A total of 170 patients were treated with either PPH01-STARR or Contour Transtar® and were followed up for a median of 18 months.

RESULTS

On preoperative defecography, 55 (32%) of 170 patients were found to have an enterocele. The preoperative Cleveland Clinic Constipation Scores (CCCS) in patients with and without enterocele were (mean ± standard deviation) 15.9 ± 5.4 and 15.4 ± 5.2, respectively. At 18 months postoperatively the CCCS were 8.5 ± 2.7 and 8.1 ± 2.6 (P < 0.001), respectively, in patients with and without enterocele. Morbidity was 7.3% (n = 4) in patients with enterocele (anal pain, n = 1; minor bleeding, n = 2; and acute urinary retention, n = 1) and 7.0% (n = 8) in patients without enterocele (anal pain, n = 3; minor bleeding, n = 3; acute urinary retention, n = 1; and staple line dehiscence, n = 1). There were no cases of pelvic sepsis, small bowel injury or postoperative ileus. No patient needed surgical re-operation.

CONCLUSION

There was no difference in functional outcome and postoperative complications in patients with and without enterocele undergoing STARR for ODS.

摘要

目的

肠膨出在患有阻塞性排便综合征(ODS)的患者中很常见,但它通常被认为是经肛吻合器直肠切除术(STARR)的禁忌证。本研究比较了伴有和不伴有肠膨出的 ODS 患者接受 STARR 治疗后的功能结果和并发症发生率。

方法

采用标准化的临床和影像学检查对患有 ODS 的患者进行评估。共有 170 例患者接受了 PPH01-STARR 或 Contour Transtar®治疗,并随访了中位数为 18 个月。

结果

术前排粪造影检查发现 170 例患者中有 55 例(32%)存在肠膨出。伴有和不伴有肠膨出的患者术前克利夫兰便秘评分(CCCS)分别为(均数±标准差)15.9±5.4 和 15.4±5.2。术后 18 个月时,伴有和不伴有肠膨出的患者 CCCS 分别为 8.5±2.7 和 8.1±2.6(P<0.001)。伴有肠膨出的患者的并发症发生率为 7.3%(n=4,分别为肛门疼痛 1 例、轻微出血 2 例和急性尿潴留 1 例),不伴有肠膨出的患者的并发症发生率为 7.0%(n=8,分别为肛门疼痛 3 例、轻微出血 3 例、急性尿潴留 1 例和吻合口裂开 1 例)。无盆腔感染、小肠损伤或术后肠梗阻病例。无患者需要再次手术。

结论

伴有和不伴有肠膨出的 ODS 患者接受 STARR 治疗后的功能结果和术后并发症无差异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验